Hopp til hovedinnhold

Pulmonal hypertensjon (PH)

Sist revidert:
Sist revidert av:
Definisjon:
Definert ved økt gjennomsnittlig hviletrykk i arteria pulmonalis (MAP) ≥ 20 mmHg i hvile. Kan være idiopatisk, eller som komplikasjon til en rekke ulike sykdommer som hjertesvikt, kroniske lungesykdommer, tromboemboli eller bindevevssykdommer
Forekomst:
Hyppigst sekundært til hjertesvikt eller kronisk lungesykdom. Idiopatisk form er sjelden: 1-2 nye tilfeller per million
Symptomer:
Symptomer er tung pust, slitenhet, synkope. Ev. symptomer på underliggende sykdom
Funn:
Ev. cyanose. EKG-forandringer forenlig med høyresidig belastning. Eventuelt ødemer, hepatomegali og halsvenestuvning ved høyresidig hjertesvikt.
Diagnostikk:
Diagnosen stilles ved ekkokardiografi og påfølgende hjertekateterisering med trykkmåling
Behandling:
Spesialistbehandling. Behandling av underliggende sykdom. Vasodilaterende behandling spesielt ved idiopatisk form. Ev. lungetransplantasjon
  1. Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG).. Eur Heart J 2022; 44: 3618-3731. pmid:36821743 PubMed  
  2. Frost A, Badesch D, Gibbs JSR, et al. Diagnosis of pulmonary hypertension. Eur Respir J 2019. pmid:30545972 PubMed  
  3. Coghlan JG, Denton CP, Grünig E, et al.; DETECT study group. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis. 2014;73(7):1340–1349.
  4. Seeger W, Adir Y, Barberà JA, et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol. 2013;62(25 suppl):D109–D116.
  5. Lam CS, Borlaug BA, Kane GC, Enders FT, Rodeheffer RJ, Redfield MM. Age-associated increases in pulmonary artery systolic pressure in the general population. Circulation 2009;119(20):2663–2670.
  6. Hoeper MM, Humbert M, Souza R, Idrees M, Kawut SM, Sliwa-Hahnle K, et al. A global view of pulmonary hypertension. Lancet Respir Med 2016;4:306–322. PMID: 26975810 PubMed  
  7. Andreassen AK, Gude E, Solberg OG, Ueland T. Behandling av idiopatisk pulmonal arteriell hypertensjon. Tidsskr Nor Legeforen 2011; 131: 1285-8. Tidsskrift for Den norske legeforening  
  8. Grigoriadis S, VonderPorten EH, Mamisashvili L, et al. Prenatal exposure to antidepressants and persistent pulmonary hypertension of the newborn: systematic review and meta-analysis. BMJ 2014; 348: f6932. BMJ (DOI)  
  9. Goh ZM, Balasubramanian N, Alabed S, et al. Right ventricular remodelling in pulmonary arterial hypertension predicts treatment response. Heart 2022; 108: 1392-1400. pmid:35512982 PubMed  
  10. Vachiéry J-L, Tedford RJ, Rosenkranz S, et al. Pulmonary hypertension due to left heart disease. Eur Respir J 2019; 53: 1801897. PMID: 30545974 PubMed  
  11. Nathan SD, Barbera JA, Gaine SP, et al. Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J 2019; 53. PMID: 30545980 PubMed  
  12. Kim NH, Delcroix M, Jais X, et al.Chronic thromboembolic pulmonary hypertension. Eur Respir J 2019; 53. PMID: 30545969 PubMed  
  13. Dunlap B, Weyer G. Pulmonary hypertension: diagnosis and treatment. Am Fam Physician 2016; 94: 463-9. American Family Physician  
  14. Strange G, Gabbay E, Kermeen F, et al. Time from symptoms to definitive diagnosis of idiopathic pulmonary arterial hypertension: the delay study. Pulm Circ. 2013;3(1):89–94.
  15. Janda S, Shahidi N, Gin K, Swiston J. Diagnostic accuracy of echocardiography for pulmonary hypertension: a systematic review and meta-analysis published correction appears in Heart. 2011;97(13):1112. Heart 2011;97(8):612–622.
  16. Klinger JR, Elliott CG, Levine DJ, et al. Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report. Chest 2019; 155: 565-86. PMID: 30660783 PubMed  
  17. Galiè N, Manes A, Negro L et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009; 30: 394 – 403
  18. Andreassen AK, Geiran O, Madsen S, et al. Pulmonal arteriell hypertensjon behandlet med prostasyklin eller kalsiumblokade. Tiddskr Nor Lægeforen 2003; 123: 3393-6. PubMed  
  19. Ghofrani H-A, Galiè N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013; 369: 330-40. New England Journal of Medicine  
  20. Ghofrani H-A, D'Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 2013; 369: 319-29. New England Journal of Medicine  
  21. Hoeper MM, Al-Hiti H, Benza RL, et al. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. Lancet Respir Med 2021; 9: 5673-84. pmid:33773120 PubMed  
  22. Hoeper MM, Badesch DB, Ghofrani HA, et al. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. N Engl J Med 2023; 388: 1478-1490. pmid:36877098 PubMed  
  23. Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347–365.
  24. Lang IM, Madani M. Update on chronic thromboembolic pulmonary hypertension. Circulation. 2014;130(6):508-18. doi: 10.1161/CIRCULATIONAHA.114.009309. DOI  
  • Ingard Løge, spesialist allmennmedisin, redaktør Norsk Elektronisk Legehåndbok